Protalix BioTherapeutics (PLX) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

Company overview and technology

• Operates a unique platform expressing complex human proteins via plant cells, with two approved products: Elelyso (Gaucher disease) and Elfabrio (Fabry disease).

• Headquarters in New Jersey, R&D and manufacturing in Israel; reported $53 million in 2024 revenue and is cash-generating.

• Clean balance sheet with no debt or warrants, and sufficient cash to support ongoing operations and clinical trials.

Product performance and commercial partnerships

• Elelyso, licensed to Pfizer, has limited commercial success despite clinical efficacy; $12 million annual sales in Brazil, with potential for future partnership changes.

• Elfabrio, commercialized by Chiesi, targets a $2.2 billion Fabry market; aims for 15%-20% market share by 2030, potentially generating $130-$150 million in sales.

• Royalty agreements with Chiesi range from 15%-40% depending on geography, plus up to $500 million in milestones.

• Chiesi’s private status limits transparency, impacting share price volatility.

Market landscape and competitive positioning

• Fabry market includes Fabrazyme (Sanofi), Replagal (Shire), and Galafold (Amicus); Elfabrio offers longer half-life and potential for once-every-four-weeks dosing.

• EMA decision on alternate dosing expected by September/October 2024; approval could significantly boost market penetration and regulatory milestones.

• If approved, once-every-four-weeks dosing could enable 25%-30% market share in approved regions.